Effect of Preoperative Oral Tramadol on Inferior Alveolar Nerve Block in Patients With Symptomatic Irreversible Pulpitis

July 13, 2021 updated by: Amr Elnaghy, Alfarabi Colleges

Effect of Preoperative Oral Tramadol on the Anaesthetic Efficacy of Inferior Alveolar Nerve Block in Patients With Symptomatic Irreversible Pulpitis: A Prospective, Randomized, Double-blind, Controlled Study

Aim: The purpose of this prospective, randomized, double-blind, controlled study was to compare the preoperative oral tramadol medication with ibuprofen and acetaminophen on the success of inferior alveolar nerve blocks (IANB) of mandibular posterior teeth in patients experiencing symptomatic irreversible pulpitis.

Methodology: The study included five study groups, each consists of 50 patients who exhibited symptomatic irreversible pulpitis of a mandibular first or second molar. The patients received identically appearing capsules containing either tramadol 50 mg, tramadol 100 mg, ibuprofen 600 mg, ibuprofen 600 mg/acetaminophen 1000 mg or placebo by mouth 60 min before the administration of an IANB. Endodontic access was begun 15 min after completion of the IANB, and all patients used for data analysis had profound lip numbness. The IANB success was defined as no or mild pain (visual analog scale recordings) on pulpal access or instrumentation. The data were analysed using chi-square χ2 and Kruskal-Wallis tests.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This study was designed as a double-blind, randomized, placebo-controlled clinical trial. This trial was carried out according to the latest update of the Declaration of Helsinki guidelines (October 2013) and approved by the Vision Colleges Research Ethics Committee (approval number 20-5/2). The patients were pre-selected to participate based on a preoperative pain scale of preliminary clinical assessment following the guidelines suggested by the CONSORT group for planning and reporting clinical trials. A total of 275 adult patients were screened for participation in this study. They were emergency patients of the Vision Colleges Dental Clinics and were in good health based on their medical histories and oral questioning. Subjects who were less than 18 years old, had a history of serious medical problems, had used central nervous system depressants or any analgesic medication within the previous 6 hours, were pregnant or were unable to give informed consent were all excluded from the study. Finally, 50 patients were enrolled in each group, for a total of 250 patients.

The inclusion criteria were active pain in a mandibular molar first or/and the second molar, prolonged response to cold testing (Endo-frost; Roeko, Langenau, Germany), absence of any periapical radiolucency on periapical radiographs, and a vital coronal pulp on access opening. The Modified Dental Anxiety Scale assessed the level of anxiety among the patients. The pain of the patients was categorized into four categories using the Heft-Parker visual analogue scale (HP VAS):

0 mm: no pain 0-54 mm: faint, weak, or mild 55-114 mm: moderate pain >114 mm: strong, intense, and maximum possible All patients were randomly divided using block randomisation to ensure the homogeneity of the five groups. The patients were randomly given tramadol 50 mg, tramadol 100 mg, ibuprofen 600 mg, ibuprofen 600 mg/acetaminophen 1000 mg or placebo by mouth 60 min before administering IANB. To blind the experiment, each of the 50 patients in each group was randomly allocated a code consists of 2 letters and one number. Only the random numbers identified the medications; thus, the patient and doctor were uninformed of which medication was given to them. The medication and placebo were blinded in the following way. In opaque yellow size "000" capsules, a certified pharmacist prepared identical-appearing capsules of the medications and placebo in identical separate containers for each medication. At 60 minutes after receiving the medication or placebo, the operator used a cotton tip applicator to put anaesthetic gel (20 percent benzocaine; Patterson Dental Supply, Inc, St Paul, MN, USA) at the IANB injection site for 60 s.

The participants were then given regular IANB injections and 0.9 mL long buccal injections containing 2% lidocaine and 1:100,000 epinephrine (Xylocaine; Astra Zeneca LP, Dentsply, York, PA, USA). The first author used self-aspirating syringes (Septodont, Sant-Maur-des-Fosses Cedex, France) and 27-G long needles to inject the anaesthetic solution (Septoject, Septodont). Each patient was asked for lip numbness every 5 min for 15 min after the IANB. The block was considered missed if substantial lip numbness was not reported by 15 min, and the participant was excluded from the trial. Due to a lack of lip numbness, no patients were excluded.

After that, a rubber dam was used to isolate the teeth and endodontic access was conducted. During the endodontic process, patients were asked to rate any pain they experienced. If the patient was in pain, the treatment was stopped, and the patient used the HP VAS to rate his/her discomfort. The success of the IANB was defined as the ability to access and clean and shape the tooth without pain (VAS score of 0) or mild pain (VAS rating ≤54 mm). The rubber dam was removed if the patient had moderate or severe pain (VAS rating ≥ 55 mm), and a buccal infiltration of a cartridge containing 4% articaine with 1:100,000 epinephrine (Septocaine; Septodont) was administrated buccally to the tooth that required emergency treatment. After 5 min, the rubber dam was replaced, and endodontic access was continued. The success of the buccal infiltration was defined as the ability to access and instrument the tooth without pain (VAS score of 0) or with mild pain (VAS rating ≤54 mm). Intraosseous anaesthesia was administrated to the patients who still had moderate to severe pain. The intraosseous injection was administrated with the Stabident intraosseous anaesthetic system (Fairfax Dental Inc, Miami, Fl, USA) using a cartridge of 2% lidocaine with 1:100,000 epinephrine as described previously. If that was not successful, an intrapulpal injection was given, and endodontic debridement was completed. The extent of access preparation and/or instrumentation was recorded as within dentine, within pulp space, and instrumentation of canals.

The VAS satisfaction form was used to record the post-treatment satisfaction of the patient. The patient was asked to draw a vertical line on the VAS (0-100 mm) to indicate their satisfaction with the entire treatment. The VAS was classified into four categories; 0: not satisfied, >0 mm and ≤33 mm: somewhat satisfied, >33 mm but <66 mm: moderately satisfied and ≥66 mm: completely satisfied.

Data of the study were collected and statistically analysed (SPSS 22.0 software; IBM Corp., Armonk, NY, USA) using chi-square χ2 test to compare between different groups for anaesthetic success, gender, and tooth type. Normality of data was tested by Shapiro-Wilk test. The Modified Dental Anxiety Scale, age, and initial pain ratings were analysed by using Kruskal-Wallis test. The level of statistical significance was set at P < 0.05. GPower v3.1.3 software (University of Düsseldorf; Düsseldorf, Germany) was used to calculate the sample size. According to a power analysis, a sample size of 50 patients per group meets the constraints of 0.05 and power = 0.95.

Study Type

Interventional

Enrollment (Actual)

250

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • active pain in a mandibular molar first or/and the second molar
  • prolonged response to cold testing
  • absence of any periapical radiolucency on periapical radiographs
  • vital coronal pulp on access opening
  • able to give informed consent

Exclusion Criteria:

  • less than 18 years old
  • history of serious medical problems
  • used central nervous system depressants or any analgesic medication within the previous 6 hours
  • pregnancy
  • inability to give informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: DOUBLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
ACTIVE_COMPARATOR: Tramadol 50
Before the inferior alveolar nerve block injection by 60 minutes, the patient received tramadol 50 mg in opaque yellow size "000" capsules.
Drug: TraMADol 50 Mg Oral Tablet
The patients were randomly given the medication by mouth 60 min before administering IANB.
Other Names:
  • TRAMAL
ACTIVE_COMPARATOR: Tramadol 100
Before the inferior alveolar nerve block injection by 60 minutes, the patient received tramadol 100 mg in opaque yellow size "000" capsules.
Drug: Tramadol 100 MG Oral Tablet
The patients were randomly given the medication by mouth 60 min before administering IANB.
Other Names:
  • TRAMAL
ACTIVE_COMPARATOR: Ibuprofen
Before the inferior alveolar nerve block injection by 60 minutes, the patient received ibuprofen 600 mg in opaque yellow size "000" capsules.
Drug: Ibuprofen 600Mg Tab
The patients were randomly given the medication by mouth 60 min before administering IANB.
Other Names:
  • IBUPROFEN
ACTIVE_COMPARATOR: Ibuprofen/acetaminophen
Before the inferior alveolar nerve block injection by 60 minutes, the patient received ibuprofen 600 mg/acetaminophen 1000 mg in opaque yellow size "000" capsules.
Drug: ibuprofen 600 mg/acetaminophen 1000 mg
The patients were randomly given the medication by mouth 60 min before administering IANB.
Other Names:
  • IBUPROFEN/PANADOL
PLACEBO_COMPARATOR: Placebo
Before the inferior alveolar nerve block injection by 60 minutes, the patient received Placebo in opaque yellow size "000" capsules.
Drug: Placebo
The patients were randomly given the medication by mouth 60 min before administering IANB.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain Measurement as Assessed on a Heft-Parker 170 mm Visual Analog Scale
Time Frame: 15 minutes after the inferior alveolar nerve block.
At 60 minutes after receiving the medication or placebo, the participants were then given inferior alveolar nerve block injection. Each patient was asked for lip numbness every 5 minutes for 15 minutes after inferior alveolar nerve block injection. During the endodontic process, patients were asked to rate any pain they experienced on a Heft-Parker visual analog scale. The number of millimeters along the scale were reported. No pain corresponded to 0 mm. Mild pain was defined as greater than 0 mm and less than or equal to 54 mm. Mild pain included the descriptors of "faint", "weak", and "mild pain". Moderate pain was defined as greater than 54 mm and less than 114 mm and included the descriptor "moderate". Severe pain was defined as equal to or greater than 114 mm up to and including 170 mm. Severe pain included the descriptors of "strong", "intense", and "maximum possible."
15 minutes after the inferior alveolar nerve block.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Postoperative Satisfaction on a 100 mm Visual Analog Scale
Time Frame: Immediately post-procedure on Day 0
Patients were rate their level of satisfaction after treatment procedure using a visual analog scale. The scale ranges from "not satisfied," to "somewhat satisfied," to "moderately satisfied," to "completely satisfied." Not satisfied corresponded to 0 mm. Somewhat satisfied was defined as greater than 0 mm and less than or equal to 33 mm. Moderately satisfied was defined as greater than 33 mm and less than 66 mm. Completely satisfied was defined as equal to or greater than 66 mm.
Immediately post-procedure on Day 0

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Alfarabi Colleges

Investigators

  • Principal Investigator: Amr M Elnaghy, PhD, Associate Professor of Endodontics

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

June 1, 2020

Primary Completion (ACTUAL)

February 28, 2021

Study Completion (ACTUAL)

February 28, 2021

Study Registration Dates

First Submitted

July 1, 2021

First Submitted That Met QC Criteria

July 10, 2021

First Posted (ACTUAL)

July 14, 2021

Study Record Updates

Last Update Posted (ACTUAL)

July 19, 2021

Last Update Submitted That Met QC Criteria

July 13, 2021

Last Verified

July 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Alfarabi

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Individual participant data that underlie the results reported in this study, after deidentification (text, tables, and figures).

IPD Sharing Time Frame

Beginning 9 months and ending 36 months following article publication.

IPD Sharing Access Criteria

For individual participant data meta-analysis

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Symptomatic Irreversible Pulpitis

Clinical Trials on TraMADol 50 Mg Oral Tablet

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe